Professional Documents
Culture Documents
Design and Optimization of Benzimidazole-Containing Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists
Design and Optimization of Benzimidazole-Containing Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists
Transient receptor potential melastatin 8 (TRPM8) is a nonselective cation channel that is thermoresponsive to cool to cold temperatures (8-28 C) and also may be activated by chemical agonists such
as menthol and icilin. Antagonism of TRPM8 activation is currently under investigation for the
treatment of painful conditions related to cold, such as cold allodynia and cold hyperalgesia. The design,
synthesis, and optimization of a class of selective TRPM8 antagonists based on a benzimidazole scaffold
is described, leading to the identification of compounds that exhibited potent antagonism of TRPM8 in
cell-based functional assays for human, rat, and canine TRPM8 channels. Numerous compounds in the
series demonstrated excellent in vivo activity in the TRPM8-selective wet-dog shakes (WDS) pharmacodynamic model and in the rat chronic constriction injury (CCI)-induced model of neuropathic pain. Taken
together, the present results suggest that the in vivo antagonism of TRPM8 constitutes a viable new
strategy for treating a variety of disorders associated with cold hypersensitivity, including certain types
of neuropathic pain.
Introduction
Transient receptor potential melastatin 8 (TRPM8a) belongs to the melastatin subgroup of the transient receptor
potential (TRP) channel superfamily. TRP channels are nonselective cation channels activated by a variety of chemical
and physical stimuli. A subset of the TRP channel superfamily
is thermoresponsive, each receptor being activated over a discrete
temperature range, cumulatively spanning from noxious cold to
noxious hot. Specifically, TRPM8 is stimulated by cool to cold
temperatures (8-28 C) and by chemical agonists such as
menthol and icilin.1
TRPM8 is expressed in a range of tissues predominately in
the prostate and liver and, to a lesser degree, in brain, lung,
bladder, gastrointestinal tract, blood vessels, and immune
cells.2,3 In addition, TRPM8 has been localized in the dorsal
root and trigeminal ganglia to subsets of primary sensory
neurons (A and C fibers) which are largely distinct from
TRPV1/TRPA1 expressing populations.1,4 Native and induced
expression of TRPM8 on multiple neuronal subtypes provides a
rationale for the observed cold hypersensitivity in numerous
*To whom correspondence should be addressed. Phone: 215-628-7860.
E-mail: mplayer@its.jnj.com.
a
Abbreviations: TRPM8, transient receptor potential melastatin 8;
LM, liver microsomes; MTCA, methyl trichloroacetamidate; ECHA,
ethyl chlorohydroximinoacetate; MTP, methylenetriphenylphosphorane;
DMBB, 3,3-dimethylbenzo[c][1,2]oxaborol-1(3H)-ol; pyBrOP, bromotripyrrolidinophosphonium hexafluorophosphate; WDS, wet-dog shakes;
CCI, chronic constriction injury; FLIPR, fluorometric imaging plate reader;
FDSS, functional drug screening system; NMR, nuclear magnetic resonance; TMS, tetramethylsilane; TLC, thin layer chromatography; HPLC,
high pressure liquid chromatography; CAM, ceric ammonium molybdate;
CSA, 10-camphorsulfonic acid.
r 2010 American Chemical Society
pubs.acs.org/jmc
234
Parks et al.
Scheme 2a
Scheme 1a
Scheme 3a
was performed by catalytic hydrogenation to yield biphenyldiamine 7. Reaction of 7 with methyl trichloroacetamidate
(MTCA) afforded 2-trichloromethylbenzimidazole 8 as a key
intermediate.10 Treatment of 8 with the appropriate amino
alcohol or diamine produced 1-3.
The spiro-isoxazoline-substituted benzimidazole series was
synthesized in a convergent manner through the assembly of
the benzimidazole five-membered ring in the final step. The
key intermediates for this step were the isoxazoline carboxylic
acid chlorides 18-20 (Scheme 2) and the biphenylnitroanilines 6, 34-47, 49 (Schemes 3 and 4).
The spiro-isoxazoline ring system was synthesized via a [3 2]
dipolar cycloaddition between the in situ generated nitrile
oxide and exo-methylenecycloalkyl (Scheme 2). Isoxazoline
ester 1211 was prepared from commercially available ethyl
nitroacetate in which the reactive dipolarophile is generated
via dehydration, whereas esters 13 and 14 were prepared by
the base-induced elimination of HCl from ethyl chlorohydroximinoacetate (ECHA). Saponification of the esters gave the
corresponding carboxylic acids 15-17, which were treated
with oxalyl chloride to afford the isoxazoline carboxylic acid
chlorides 18-20.
Biphenylnitroanilines 6, 34-45 were prepared by Suzuki
coupling from the 4-halo-2-nitroanilines 21-23 and 2substituted phenylboronic acids 24-27 (Scheme 3). In some
a
Reagents and conditions: (a) (dppf)PdCl2 3 DCM, DME, 2 M aq
Na2CO3, 90 C; (b) ArX, (dppf)PdCl2 3 DCM, DME, 2 M aq Na2CO3,
90 C. Bpin = 4,4,5,5-tetramethyl-1,3,2-dioxaborolyl.
Article
Scheme 4a
Reagents and conditions: (a) NCS, ACN, 80 C, 72 h; (b) Br2, AcOH, rt,
30 min; (c) I2, Ag2SO4, EtOH, rt, 24 h; (d) CuCN, DMA, 140 C, 14 h;
(e) propargyl alcohol, (Ph3P)2PdCl2, CuI, THF, TEA, rt, 16 h; (f) H2,
10% Pd on C, EtOH, rt, 16 h; (g) TBSCl, imidazole, DCM, rt, 2 h.
a
Scheme 6a
a
Reagents and conditions: (a) 18, TEA, DCM, rt, 1 h; (b) dioxane,
CSA, 100 C, 3 h; (c) DMBB or 27, (dppf)PdCl2 3 DCM, DME, 2 M aq
Na2CO3, 90 C.
236
Parks et al.
Table 2. SAR for Substitution on the 5-Phenyl Ring
a
IC50 values or % inhibition at a test concentration of 0.2 M
averaged from four determinations (n = 4). b Percent remaining after
10 min incubations in human (HLM), rat (RLM), or dog (DLM) liver
microsomal preparations.
a
Percent remaining after 10 min incubations in human (HLM), rat
(RLM), or dog (DLM) liver microsomal preparations.
Article
Table 3. Functional Activity of Substitution of R1 and Z
compd
4
60
61
62
63
64
5
65
66
67
R1
cTRPM8
IC50
(nM)
-CF3 -H
-CF3 -F
-CF3 -Cl
-CF3 -CN
-CF3 -Br
-F
-CF3
-CF3 -CF3
-OCF3-CF3
-Cl
-CF3
-CF3 -(CH2)3OH
3.1
2.2
3.3
0.7
2.7
1.7
0.8
1.2
1.0
0.2
stabilitya
HLM/
CYP 2C9 IC50
(M)b
RLM/DLM
100/75/71
46/100/87
92/100/100
68/96/51
100/83/74
71/100/82
92/79/59
51/53/50
66/100/60
57/74/12
1.7
6.4
6.0
1.9
2.2
10
10
10
10
6.8
compd
R1
cTRPM8 IC50
(nM)
stabilitya HLM/
RLM/DLM
68
69
70
71
-CF3
-CF3
-CF3
-CF3
-H
-H
-CF3
-Cl
O
CF2
O
O
6.7
0.9
1.4
4.0
98/74/83
66/ndb/34
100/96/90
100/82/81
a
Percent remaining after 10 min incubations in human (HLM), rat
(RLM), or dog (DLM) liver microsomal preparations. b Not determined.
Figure 3. Inhibition of cold-stimulated currents in HEK cells expressing canine and human TRPM8. Sequential concentrations of 5 were
applied following steady-state current activation achieved by cooling
perfusate to 10 C (from 22 C).
238
Parks et al.
The potent TRPM8 antagonists 5 and 64-66, which displayed relatively high metabolic stability and the lowest CYP
2C9 inhibitory activities, were further scrutinized in the WDS
PD assay. All four compounds completely prevented icilininduced WDS at oral doses of 10 mg/kg; therefore, the rat
CCI cold allodynia model was used as a means to discriminate
the compounds. All compounds demonstrated efficacy in the
CCI model, albeit to different degrees. At an oral dose of
10 mg/kg, 5 gave the greatest reversal of 91%, whereas 64-66
peaked at 51%, 74%, and 74%, respectively, after 2 h postdose
(Figure 2).
Table 5. Pharmacokinetic Assessment of 5 in Rat, Dog, And Cynomolgous Monkey after Intravenous and Oral Administration
intravenous administration
oral administration
species
CL (mL/min/kg)
Vdss (L/kg)
t1/2 (h)
Cmax (ng/mL)
t1/2 (h)
F (%)
rata
dogb
monkeya
13.9
14.5
15.4
2.92
4.43
4.92
3.17
ndc
5.66
1262
1641
510
12302
5252
6184
4.74
5.79
4.98
96
45
57
a
Rats and monkeys were administered 2 mg/kg iv of the HCl salt in 20% HPCD or 10 mg/kg po in 20% HPCD. b Dogs were administered 2 mg/kg
iv of the free form in 20% HPCD or 10 mg/kg po in 20% HPCD. c Not determined.
Article
240
Parks et al.
and (dppf)PdCl2 3 DCM (145 mg, 0.178 mmol) in DME (15 mL)
and 2 M aq Na2CO3 (5 mL, 10 mmol) according to the general
Suzuki procedure, yielding an orange solid (1.05 g, 94%). 1H
NMR (400 MHz, CDCl3) : 8.47 (d, J = 2.0 Hz, 1H), 7.89
(d, J = 2.0 Hz, 1H), 7.47-7.53 (m, 1H), 7.30-7.37 (m, 3H), 6.76
(br s, 2H).
20 -(Trifluoromethyl)-[1,10 -biphenyl]-3,4-diamine (7). Biphenylnitroaniline 6 (818 mg, 2.90 mmol) was dissolved in absolute
EtOH (10 mL) then 10% Pd on carbon was added. The reaction
was stirred at rt under a H2 atmosphere at balloon pressure for 15 h.
The H2 was vented then the suspension was filtered. The solids were
washed with MeOH (3 10 mL), and then the combined filtrates
were concentrated under reduced pressure. The crude product was
chromatographed on a 24 g SiO2 prepacked column eluting with
0:1 to 4:1 EtOAc/hexanes, affording the title compound as an offwhite solid (570 mg, 78%). 1H NMR (400 MHz, CDCl3) : 7.69
(d, J = 8.1 Hz, 1H), 7.49 (t, J = 7.1 Hz, 1H), 7.39 (t, J = 7.5 Hz,
1H), 7.31 (d, J = 7.6 Hz, 1H), 6.64-6.73 (m, 3H), 3.41 (br s, 4H).
2-(Trichloromethyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzimidazole (8). Biphenyl diamine 7 (222 mg, 0.880 mmol) was dissolved
in AcOH (4 mL) then treated with methyl 2,2,2-trichloroacetimidate (MTCA) (0.120 mL, 0.968 mmol) and stirred at rt for 14 h.
The reaction was poured into H2O (50 mL), and the resulting
precipitate was isolated by filtration. The solid was washed with
H2O (2 10 mL) and then dissolved in EtOAc (50 mL) and
dried over MgSO4. The solution was filtered and then concentrated under reduced pressure. The residue was triturated with
a minimum amount of DCM, affording the title compound as a
yellow powder (326 mg, 100%). 1H NMR (400 MHz, CDCl3)
: 10.46 (br s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.57 (t, J = 7.6 Hz,
1H), 7.49 (t, J = 7.6 Hz, 1H), 7.38-7.93 (br s, m, 2H), 7.29-7.38
(m, 2H). Mass spectrum (LCMS, ESI pos.) calcd for
C15H8Cl3F3N2 (M H) 379.0, found 379.0.
2-(5-(2-(Trifluoromethyl)phenyl)-1H-benzimidazol-2-yl)-1oxa-3-azaspiro[4.5]dec-2-ene (1). 1-(Aminomethyl)cyclohexanol
hydrochloride (294 mg, 1.77 mmol) was dissolved in H2O
(8 mL) and treated with 2 M NaOH (0.890 mL, 1.77 mmol),
and then a dioxane (16 mL) solution of 8 (163 mg, 0.443
mmol) was added. The reaction was stirred at rt for 14 h and
then diluted with brine (30 mL) and extracted with EtOAc
(3 20 mL). The combined organic extracts were dried over
MgSO4 and concentrated under reduced pressure. The crude
product was chromatographed on a 24 g SiO2 prepacked
column eluting with 0:1 to 2:5 EtOAc/hexanes, affording the
title compound (114 mg, 64%). 1H NMR (400 MHz, CD3OD)
: 7.79 (d, J = 7.8 Hz, 1H), 7.73 (br s, 1H), 7.65 (t, J = 7.2 Hz,
1H), 7.60 (br. s, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.43 (d, J =
7.6 Hz, 1H), 7.29 (br. d, J = 6.8 Hz, 1H), 3.84 (s, 2H), 1.80-1.98
(m, 4H), 1.69-1.79 (m, 2H), 1.43-1.65 (m, 4H). HRMS calcd for
C22H20F3N3O (M H) 400.1637, found 400.1630.
2-(5-(2-(Trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-yl)-3oxa-1-azaspiro[4.5]dec-1-ene (2). (1-Aminocyclohexyl)methanol20
(172 mg, 1.33 mmol) was dissolved in H2O (8 mL), and then a
dioxane (16 mL) solution of 8 (164 mg, 0.445 mmol) was added.
The reaction was stirred at rt for 14 h and then diluted with brine
(30 mL) and extracted with EtOAc (3 20 mL). The combined
organic extracts were dried over MgSO4 and concentrated under
reduced pressure. The crude product was chromatographed on a
24 g SiO2 prepacked column eluting with 0:1 to 2:5 EtOAc/hexanes,
affording the title compound (13.9 mg, 7.8%). 1H NMR (400 MHz,
CD3OD) : 7.79 (d, J = 7.8 Hz, 1H), 7.71 (br s, 1H), 7.65 (t, J =
7.2 Hz, 1H), 7.62 (br s, 1H), 7.56 (t, J = 7.7 Hz, 1H), 7.42 (d, J =
7.6 Hz, 1H), 7.29 (d, J = 6.6 Hz, 1H), 4.32 (s, 2H), 1.75-1.94 (m,
4H), 1.65-1.75 (m, 2H), 1.41-1.65 (m, 4H). HRMS calcd for
C22H20F3N3O (M H) 400.1637, found 400.1636.
2-(1,3-Diazaspiro[4.5]dec-2-en-2-yl)-5-(2-(trifluoromethyl)phenyl)-1H-benzimidazole Hydrochloride (3). A mixture of
1-(aminomethyl)cyclohexylamine dihydrochloride21 (54.1 mg,
0.269 mmol) and 8 (102 mg, 0.269 mmol) in 8 mL of THF
was treated with TEA (0.262 mL, 1.88 mmol) and stirred for 1 h.
Article
242
1.16 g, 3.72 mmol) was added in one portion as a solid, and the
reaction was stirred at rt for 24 h. The reaction was filtered, and
then the solvent was removed under reduced pressure. The residue
was dissolved in DCM (30 mL), washed with 10% aq Na2S2O3
(10 mL), dried over anhydrous MgSO4 and filtered, and then the
solvent was removed under reduced pressure. The crude product
was purified by column chromatography using a 40 g SiO2
prepacked column eluting with 0:1 to 1:4 EtOAc/hexanes, yielding
an orange solid (902 mg, 83%). 1H NMR (400 MHz, CDCl3)
: 8.17 (d, J = 2.0 Hz, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.76 (d, J =
7.3 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.50 (t, J = 7.7 Hz, 1H),
7.32 (d, J = 7.6 Hz, 1H), 6.74 (br s, 2H).
4-Amino-5-nitro-20 -(trifluoromethyl)-[1,10 -biphenyl]-3-carbonitrile
(49). Biphenyl nitroaniline 48 (230 mg, 0.564 mmol) and Cu(I)CN (1.5 equiv, 7.57 mg, 0.845 mmol) were placed in an 8 mL vial
equipped with a magnetic stir bar. Dry dimethylacetamide (2.5 mL)
was added, and the vial was tightly capped and was stirred at 140 C
for 14 h. The reaction was cooled to rt and then poured into
water. The precipitate was isolated by filtration and washed with
water (10 mL). The precipitate was dissolved in EtOAc (25 mL),
dried over anhydrous MgSO4, and filtered, and then the solvent
was removed under reduced pressure. The crude product was
purified by preparative TLC on a 2000 m SiO2 plate developed
with 1:9 EtOAc/hexanes, yielding a yellow solid (86 mg, 50%).
1
H NMR (400 MHz, CDCl3) : 8.37 (d, J = 1.8 Hz, 1H), 7.79
(d, J = 7.8 Hz, 1H), 7.71 (d, J = 1.5 Hz, 1H), 7.62 (t, J = 7.3 Hz,
1H), 7.55 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 6.84
(br s, 2H).
3-(4-Amino-5-nitro-20 -(trifluoromethyl)-[1,10 -biphenyl]-3-yl)prop-2-yn-1-ol (50). Biphenyl nitroaniline 48 (466 mg, 1.14 mmol),
(Ph3P)2 PdCl 2 (0.05 equiv, 40.1 mg, 0.057 mmol), and CuI
(0.05 equiv, 10.2 mg, 0.054 mmol) were placed in a 40 mL vial
equipped with a magnetic stir bar. The vial was evacuated and
backflushed with argon, and then anhydrous THF (6 mL) and TEA
(4.0 equiv, 0.64 mL, 4.56 mmol) were added. Propargyl alcohol
(4 equiv, 0.270 mL, 4.56 mmol) was added, and then the reaction
was stirred at rt for 16 h. The solution was diluted with EtOAc
(20 mL) and filtered. The solvent was removed under reduced
pressure, and the crude product was purified by column chromatography on a 24 g SiO2 prepacked column eluting with 0:1 to
3:2 EtOAc/hexanes, yielding the title compound (279 mg, 73%). 1H
NMR (400 MHz, CDCl3) : 8.10 (d, J = 2.0 Hz, 1H), 7.73 (d, J =
7.6 Hz, 1H), 7.53-7.59 (m, 1H), 7.53 (d, J = 1.8 Hz, 1H),
7.43-7.51 (m, 1H), 7.29 (d, J = 7.6 Hz, 1H), 6.82 (br s, 2H), 4.59
(s, 2H).
3-(4,5-Diamino-2 0 -(trifluoromethyl)-[1,1 0 -biphenyl]-3-yl)propan-1-ol (51). Biphenyl nitroaniline 50 (148 mg, 0.440 mmol)
was placed in an 8 mL vial equipped with a magnetic stir bar, and
then dry EtOH (2 mL) was added. To the ethanol solution was
added 10% Pd on activated carbon (27 mg), and then the reaction
was stirred under an atmosphere of H2 at balloon pressure for 16 h.
The H2 was released, and then the reaction was filtered. The filter
cake was washed three times with MeOH (5 mL). The filtrates were
combined then the solvent was removed under reduced pressure to
afford the title compound (101 mg, 73%). 1H NMR (400 MHz,
CDCl3) : 7.68 (d, J = 7.6 Hz, 1H), 7.48 (t, J = 7.3 Hz, 1H), 7.38
(t, J = 7.6 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 6.61 (s, 1H), 6.60
(s, 1H), 3.65 (t, J = 5.9 Hz, 2H), 3.48 (br s, 4H), 2.66 (t, J =
7.3 Hz, 2H), 1.86 (quin, J = 6.6 Hz, 2H).
5-(3-((tert-Butyldimethylsilyl)oxy)propyl)-20 -(trifluoromethyl)[1,10 -biphenyl]-3,4-diamine (52). Biphenyldiamine 51 (101 mg,
0.324 mmol) was dissolved in DCM (2 mL), and then imidazole
(1.1 equiv, 24.5 mg, 0.356 mmol) and TBSCl (1.1 equiv, 53.7 mg,
0.356 mmol) were added sequentially. The reaction was stirred
at rt for 2 h. The reaction was filtered, the precipitate was washed
once with DCM (5 mL), and the filtrate was concentrated under
reduced pressure. The crude product was purified by column
chromatography on a 24 g SiO2 prepacked column eluting with
0:1 to 1:1 EtOAc/hexanes, yielding the title compound (93.2 mg,
68%). 1H NMR (400 MHz, CDCl3) : 7.69 (d, J = 7.8 Hz, 1H),
Parks et al.
7.49 (t, J = 7.5 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.32 (d, J =
7.6 Hz, 1H), 6.61 (s, 1H), 6.59 (s, 1H), 3.66 (t, J = 5.9 Hz, 2H),
3.52 (br s, 4H), 2.65 (t, J = 7.3 Hz, 2H), 1.75-1.87 (m, 2H), 0.91
(s, 9H), 0.07 (s, 6H).
Preparation of the Spiro-isoxazoline Benzimidazoles 4, 5,
53-69: General Procedure. The biphenylnitroaniline (1 equiv)
was dissolved in a mixture of EtOH and 3 M HCl (5:1), and then
Fe powder (5 equiv) was added and the reaction was stirred at
80 C for 4 h. The reaction was cooled to rt and filtered. The
solids were washed with MeOH, and then the combined filtrates
were concentrated under reduced pressure. To the residue was
added 2 M NaOH (10 mL), and then the aqueous mixture was
extracted with EtOAc (3 15 mL). The organic extracts were
combined, dried over MgSO4, and filtered. The solvent was
removed under reduced pressure to afford the biphenyldiamine,
which was used without purification in the next step.
The biphenyldiamine (1.12 equiv) was dissolved in DCM, and
then TEA (3 equiv) was added. A DCM solution of the spiroisoxazoline acid chloride was added dropwise over 10 min, and
then the reaction was stirred at rt for 2 h. The solvent was removed
under reduced pressure, and then the residue was purified by column
chromatography to afford a mixture of the two monoamides.
The monoamide mixture was dissolved in dry dioxane, and
then CSA (0.2 equiv) was added and the reaction was stirred at
100 C for 4 h. The reaction was cooled to rt and then poured
into a saturated aqueous NaHCO3 solution and extracted with
EtOAc (3). The combined organic extracts were dried over
MgSO4 and filtered, and then the solvent was removed under
reduced pressure. The residue was purified by chromatography
to afford the desired benzimidazole.
Optionally, a salt form of the benzimidazole was prepared
using the following general procedure: The benzimidazole was
dissolved in EtOAc, and then 1 M HCl in Et2O (1 equiv) was
added. A precipitate immediately formed, which was isolated by
filtration and rinsed once with EtOAc. The residual solvent was
removed under high vacuum to afford the benzimidazole hydrochloride salt.
3-[5-(2-Trifluoromethyl-phenyl)-1H-benzimidazol-2-yl]-1-oxa-2aza-spiro[4.5]dec-2-ene (4). The title compound was prepared
according to the general procedure from biphenyldiamine 7
(157 mg, 0.626 mmol) and TEA (1.00 mL, 7.17 mmol) dissolved
in DCM (20 mL) by slow addition of acid chloride 18 (0.796 mmol)
in DCM (30 mL), affording a mixture of the monoamides (172 mg,
79%). The monoamide mixture (172 mg, 0.413 mmol) in dioxane
(6 mL) was treated with TsOH 3 H2O (78.5 mg, 0.413 mmol) at
80 C for 14 h, yielding a white foam (67.8 mg, 41%). 1H NMR
(400 MHz, CD3OD) : 7.79 (d, J = 7.8 Hz, 1H), 7.65 (td, J =
7.6, 0.8 Hz, 1H), 7.64 (br s, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.54
(br s, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 3.29
(s, 2H), 1.71-1.91 (m, 6H), 1.48-1.64 (m, 4H). HRMS calcd for
C22H20F3N3O (M H) 400.1637, found 400.1629.
3-[7-Trifluoromethyl-5-(2-trifluoromethyl-phenyl)-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene Hydrochloride (5). The title
compound was prepared according to the general procedure from
nitroaniline 43 (330 mg, 0.942 mmol) and Fe powder (263 mg,
4.71 mmol) in EtOH (5 mL) and 3 M HCl (1 mL) in the first step,
and then the resulting biphenyldiamine (0.942 mmol) and TEA
(0.330 mL, 2.39 mmol) dissolved in DCM (50 mL) was treated with
acid chloride 18 (0.796 mmol) in DCM (30 mL), affording a mixture
of the monoamides (272 mg, 70%). The monoamide mixture
(272 mg, 0.560 mmol) in dioxane (10 mL) was treated with CSA
(26.0 mg, 0.112 mmol) at 100 C for 3 h, yielding a white foam
(255 mg, 97%). Treatment of the benzimidazole (255 mg,
0.545 mmol) in EtOAc (3 mL) with 1 M HCl in Et2O (0.55 mL,
0.550 mmol) afforded the title compound as a white powder
(241 mg, 88%). 1H NMR (400 MHz, DMSO-d6) : 7.89 (d, J =
7.6 Hz, 1H), 7.74-7.81 (m, 1H), 7.71 (s, 1H), 7.65-7.70 (m, 1H),
7.56 (d, J = 7.6 Hz, 1H), 7.48 (s, 1H), 3.33 (s, 2H), 1.63-1.82
(m, 6H), 1.35-1.55 (m, 4H). HRMS calcd for C23H19F6N3O (M
H) 468.1511, found 468.1515.
Article
1.0 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 7.67 (dd, J = 8.5, 1.6 Hz, 1H),
7.55 (dd, J = 8.0, 1.1 Hz, 1H), 7.41 (dd, J = 8.1, 1.3 Hz, 1H), 7.34
(t, J = 8.1 Hz, 1H), 1.63-1.82 (m, 6H), 1.37-1.55 (m, 4H). HRMS
calcd for C22H19F2N3O3 (M H) 412.1473, found 412.1486.
3-[5-(2,6-Difluorophenyl)-1H-benzimidazol-2-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene Trifluoroacetic Acid Salt (57). The title compound was prepared according to the general procedure from
nitroaniline 38 (204 mg, 0.815 mmol) and Fe powder (228 mg,
4.08 mmol) in EtOH (5 mL) and 3 M HCl (1.5 mL) in the first
step, and then the resulting biphenyldiamine (0.762 mmol) and
TEA (0.290 mL, 2.08 mmol) dissolved in DCM (30 mL) was
treated with acid chloride 18 (0.508 mmol) in DCM (20 mL),
affording a mixture of the monoamides (154 mg, 79%). The
monoamide mixture (154 mg, 0.400 mmol) in dioxane (4 mL)
was treated with CSA (19.0 mg, 0.080 mmol) at 100 C for 4 h.
The product was further purified by HPLC, affording the title
compound as the trifluoroacetic acid salt (121 mg, 63%). 1H
NMR (400 MHz, DMSO-d6) : 7.70 (d, J = 8.3 Hz, 1H), 7.66
(s, 1H), 7.43-7.54 (m, 1H), 7.33 (dd, J = 8.6, 1.3 Hz, 1H),
7.19-7.29 (m, 2H), 3.30 (s, 2H), 1.63-1.79 (m, 6H), 1.35-1.55
(m, 4H). HRMS calcd for C21H19F2N3O (M H) 368.1574,
found 368.1590.
3-[5-(2-Fluoro-6-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1oxa-2-aza-spiro[4.5]dec-2-ene (58). The title compound was prepared according to a modified general procedure from nitroaniline
39 (754 mg, 2.51 mmol), NH4Cl (1.34 g, 25.1 mmol), and Fe powder
(701 mg, 12.6 mmol) in EtOH (20 mL) and H2O (5 mL) stirred at
80 C for 14 h, affording the biphenyldiamine (662 mg, 98%) in
the first step, and then the resulting biphenyldiamine (258 mg,
0.953 mmol) and TEA (0.360 mL, 2.55 mmol) dissolved in DCM
(50 mL) was treated with acid chloride 18 (0.851 mmol) in DCM
(10 mL), affording a mixture of the monoamides (315 mg, 85%).
The monoamide mixture (315 mg, 0.723 mmol) in dioxane (6 mL)
was treated with CSA (34.0 mg, 0.145 mmol) at 100 C for
4 h, yielding a white foam (151 mg, 50%). 1H NMR (400 MHz,
DMSO-d6 TFA-d1) : 7.63-7.77 (m, 4H), 7.57 (s, 1H), 7.23
(d, J = 8.3 Hz, 1H), 3.31 (s, 2H), 1.63-1.85 (m, 6H), 1.34-1.59
(m, 4H). HRMS calculated for C22H19F4N3O (M H) 418.1543,
found 418.1552.
3-[5-(2-Fluoro-6-trifluoromethoxyphenyl)-1H-benzimidazol-2-yl]1-oxa-2-aza-spiro[4.5]dec-2-ene Hydrochloride (59). The title compound was prepared according to the general procedure from nitroaniline 40 (285 mg, 0.901 mmol) and Fe powder (252 mg,
4.51 mmol) in EtOH (5 mL) and 3 M HCl (1 mL) in the first step,
and then the resulting biphenyldiamine (0.831 mmol) and TEA
(0.310 mL, 2.23 mmol) dissolved in DCM (50 mL) was treated with
acid chloride 18 (0.742 mmol) in DCM (10 mL), affording a mixture
of the monoamides (269 mg, 80%). The monoamide mixture
(269 mg, 0.595 mmol) in dioxane (6 mL) was treated with CSA
(28.0 mg, 0.119 mmol) at 100 C for 4 h, yielding a white
foam (121 mg, 47%). Treatment of the benzimidazole (113 mg,
0.261 mmol) in EtOAc (2 mL) with 1 M HCl in Et2O (0.260 mL,
0.260 mmol) afforded the title compound as a white powder
(112 mg, 91%). 1H NMR (400 MHz, DMSO-d6) : 7.72 (d, J =
8.3 Hz, 1H), 7.63 (s, 1H), 7.55-7.62 (m, 1H), 7.45 (t, J = 8.8 Hz,
1H), 7.40 (d, J = 8.3 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 3.31 (s, 2H),
1.63-1.80 (m, 6H), 1.33-1.57 (m, 4H). HRMS calcd for
C22H19F4N3O2 (M H) 434.1492, found 434.1494.
3-[7-Fluoro-5-(2-trifluoromethylphenyl)-1H-benzimidazol2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene Hydrochloride (60). The title
compound was prepared according to the general procedure from
nitroaniline 41 (300 mg, 1.00 mmol) and Fe powder (279 mg,
5.00 mmol) in EtOH (5 mL) and 3 M HCl (1 mL) in the first step,
and then the resulting biphenyldiamine (0.561 mmol) and TEA
(0.210 mL, 1.53 mmol) dissolved in DCM (30 mL) was treated with
acid chloride 18 (0.510 mmol) in DCM (20 mL), affording a mixture
of the monoamides (140 mg, 63%). The monoamide mixture
(140 mg, 0.322 mmol) in dioxane (2 mL) was treated with CSA
(15.0 mg, 0.064 mmol) at 100 C for 3 h, yielding a white foam
(116 mg, 86%). Treatment of the benzimidazole (116 mg,
244
Parks et al.
4.45 mmol) in EtOH (5 mL) and 3 M HCl (1 mL) in the first step,
and then the resulting biphenyldiamine (0.892 mmol) and TEA
(0.330 mL, 2.39 mmol) dissolved in DCM (50 mL) was treated with
acid chloride 18 (0.796 mmol) in DCM (30 mL), affording a mixture
of the monoamides (256 mg, 74%). The monoamide mixture
(256 mg, 0.589 mmol) in dioxane (10 mL) was treated with CSA
(27.3 mg, 0.118 mmol) at 100 C for 3 h, yielding a white foam
(242 mg, 98%). Treatment of the benzimidazole (242 mg,
0.579 mmol) in EtOAc (3 mL) with 1 M HCl in Et2O (0.580 mL,
0.580 mmol) afforded the title compound as a white powder
(211 mg, 80%). 1H NMR (400 MHz, DMSO-d6) : 7.92 (s, 1H),
7.71 (s, 1H), 7.62-7.70 (m, 1H), 7.44-7.52 (m, 1H), 7.32-7.41 (m,
2H), 3.33 (s, 2H), 1.61-1.83 (m, 6H), 1.35-1.59 (m, 4H). HRMS
calcd for C22H19F4N3O (M H) 418.1543, found 418.1542.
3-[5-(2-Trifluoromethoxyphenyl)-7-trifluoromethyl-1H-benzimidazol-2-yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene Hydrochloride (65).
The title compound was prepared according to the general procedure from nitroaniline 44 (326 mg, 0.890 mmol) and Fe powder
(249 mg, 4.45 mmol) in EtOH (5 mL) and 3 M HCl (1 mL) in
the first step, and then the resulting biphenyldiamine (294 mg,
0.876 mmol) and TEA (0.330 mL, 2.39 mmol) dissolved in DCM
(50 mL) was treated with acid chloride 18 (0.796 mmol) in DCM
(30 mL), affording a mixture of the monoamides (276 mg, 69%).
The monoamide mixture (276 mg, 0.550 mmol) in dioxane (10 mL)
was treated with CSA (25.6 mg, 0.110 mmol) at 100 C for 3 h,
yielding a white foam (252 mg, 95%). Treatment of the benzimidazole (252 mg, 0.521 mmol) in EtOAc (3 mL) with 1 M HCl in
Et2O (0.520 mL, 0.520 mmol) afforded the title compound as a
white powder (232 mg, 86%). 1H NMR (400 MHz, DMSO-d6)
: 7.86 (s, 1H), 7.66-7.73 (m, 1H), 7.64 (s, 1H), 7.50-7.62 (m,
3H), 3.33 (s, 2H), 1.62-1.83 (m, 6H), 1.34-1.61 (m, 4H). HRMS
calcd for C23H19F6N3O2 (M H) 484.1460, found 484.1458.
3-[5-(2-Chlorophenyl)-7-trifluoromethyl-1H-benzimidazol-2-yl]-1oxa-2-aza-spiro[4.5]dec-2-ene Hydrochloride (66). The title compound was prepared according to the general procedure from
nitroaniline 45 (291 mg, 0.918 mmol) and Fe powder (256 mg,
4.59 mmol) in EtOH (5 mL) and 3 M HCl (1 mL) in the first step,
and then the resulting biphenyldiamine (266 mg, 0.929 mmol) and
TEA (0.330 mL, 2.39 mmol) dissolved in DCM (50 mL) was treated
with acid chloride 18 (0.796 mmol) in DCM (30 mL), affording a
mixture of the monoamides (233 mg, 65%). The monoamide
mixture (233 mg, 0.517 mmol) in dioxane (10 mL) was treated with
CSA (24.0 mg, 0.103 mmol) at 100 C for 3 h, yielding a white
foam (156 mg, 70%). Treatment of the benzimidazole (156 mg,
0.359 mmol) in EtOAc (2 mL) with 1 M HCl in Et2O (0.360 mL,
0.360 mmol) afforded the title compound as a white powder
(115 mg, 68%). 1H NMR (400 MHz, DMSO-d6) : 13.52 (br s,
1H), 7.86 (d, J = 7.6 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.65 (t, J =
7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.35 (s, 1H), 7.25 (s, 1H), 3.33
(s, 2H), 1.63-1.82 (m, 6H), 1.33-1.59 (m, 4H). HRMS calcd for
C22H19ClF3N3O (M H) 434.1247, found 434.1245.
3-[2-(1-Oxa-2-aza-spiro[4.5]dec-2-en-3-yl)-6-(2-trifluoromethylphenyl)-3H-benzimidazol-4-yl]-propan-1-ol Hydrochloride (67).
The title compound was prepared according to the general procedure from biphenyldiamine 52 (93.2 mg, 0.220 mmol) and
TEA (0.0840 mL, 0.600 mmol) dissolved in DCM (20 mL) by
slow addition of acid chloride 18 (0.200 mmol) in DCM (10 mL),
affording a mixture of the monoamides, which was used as crude
material in the next step. The monoamide mixture (0.200 mmol)
in dioxane (6 mL) was treated with CSA (9.0 mg, 0.040 mmol) at
100 C for 3 h, during which time the silyl ether was cleaved
concurrently with the cyclization, affording the hydroxypropylbenzimidazole (51.3 mg, 56%). Treatment of the benzimidazole
(51.3 mg, 0.112 mmol) in EtOAc (2 mL) with 1 M HCl in Et2O
(0.110 mL, 0.110 mmol) afforded the title compound as a white
powder (48.6 mg, 88%). 1H NMR (400 MHz, DMSO-d6) : 7.85
(d, J = 7.6 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.63 (t, J = 7.6 Hz,
1H), 7.48 (d, J = 7.3 Hz, 1H), 7.37 (s, 1H), 7.08 (s, 1H), 3.45
(t, J = 6.6 Hz, 2H), 3.33 (s, 2H), 3.01 (t, J = 7.5 Hz, 2H),
1.79-1.90 (m, 2H), 1.61-1.79 (m, 6H), 1.31-1.57 (m, 4H).
Article
246
Parks et al.
References
(1) (a) McKemy, D. D.; Neuhausser, W. M.; Julius, D. Identification
of a cold receptor reveals a general role for TRP channels in
thermosensation. Nature 2002, 416, 5258. (b) Peier, A. M.; Moqrich,
A.; Hergarden, A. C.; Reeve, A. J.; Andersson, D. A.; Story, G. M.;
Earley, T. J.; Dragoni, I.; McIntyre, P.; Bevan, S.; Patapoutian, A. ATRP
channel that senses cold stimuli and menthol. Cell 2002, 108, 705715.
(c) Kuhn, F. J. P.; Kuhn, C.; Luckhoff, A. Inhibition of TRPM8 by Icilin
distinct from desensitization induced by menthol derivatives. J. Biol.
Chem. 2009, 284, 41024111.
(2) Fonfria, E.; Murdock, P. R.; Cusdin, F. S.; Benham, C. D.; Kelsell,
R. E.; McNulty, S. J. Recept. Signal Transduction 2006, 26, 159178.
(3) Voets, T.; Owsianik, G.; Nilius, B. Transient Receptor Potential
(TRP) Channels. In Handbook of Experimental Pharmacology;
Flockerzi, V. Nilius, B., Eds.; Springer: Berlin, 2007; pp 329-330.
(4) (a) Nealen, M. L.; Gold, M. S.; Thut, P. D.; Caterina, M. J. TRPM8
mRNA is expressed in a subset of cold-responsive trigeminal neurons
from rat. J. Neurophysiol. 2003, 90, 515520. (b) Kobayashi, K.;
Fukuoka, T.; Obata, K.; Yamanaka, H.; Dai, Y.; Tokunaga, A.; Noguchi,
K. Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat
primary afferent neurons with A/C-fibers and co-localization with TRK
receptors. J. Comp. Neurol. 2005, 493, 596606.
(5) (a) Roza, C.; Belmonte, C.; Viana, F. Cold sensitivity in axotomized fibers of experimental neuromas in mice. Pain 2006, 120, 24
35. (b) Colburn, R. W.; Lubin, M. L.; Stone, D. J., Jr.; Wang, Y.;
Lawrence, D.; D'Andrea, M. R.; Brandt, M. R.; Liu, Y.; Flores, C. M.;
Qin, N. Attenuated cold sensitivity in TRPM8 null mice. Neuron 2007,
54, 379386.(c) Caspani, O.; Zurborg, S.; Labuz, D.; Heppenstall, P. A.
The contribution of TRPM8 and TRPA1 channels to cold allodynia and
neuropathic pain. PLoS ONE, 2009, 4, e7383, doi 10.1371/journal.
pone.0007383.(d) Xing, H.; Chen, M.; Ling, J.; Tan, W.; Gu, J. G.
TRPM8 mechanism of cold allodynia after chronic nerve injury.
J. Neurosci. 2007, 27, 1368013690.
(6) (a) Ji, R.-R.; Kohno, T.; Moore, K. A.; Woolf, C. J. Central
sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003, 26, 696705. (b) Takahashi, K.; Sato, J.;
Mizumura, K. Responses of C-fiber low threshold mechanoreceptors and
nociceptors to cold were facilitated in rats persistently inflamed and
hypersensitive to cold. Neurosci. Res. 2003, 47, 409419.(c) Allchorne,
Article
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)